Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (5121)	8/24/1998 9:01:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Oops. sorry. Thread, ignore 5118. Thanks for the correction, James. <eom>

To: James Baker who wrote (5121)	8/24/1998 10:13:00 AM
From: Anthony Wong	Respond to of 9523

08/24 09:49 Monsanto <MTC.N> says Celebra gets priority status ST. LOUIS, Aug 24 (Reuters) - Monsanto's G.D. Searle & Co. said Monday that its Celebra arthritis drug has received priority review designation from the Food and Drug administration. Celebra's submitted indication is for acute or chronic use in the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and for pain management. Searle and Pfizer Inc. <PFE.N> will develop and sell Celebra in all areas of the world except Japan. moneynet.com@NEWS-P2&Index=0&HeadlineURL=../News/NewsHeadlines.asp&DISABLE_FORM=